News Headlines Article

Are hep C exclusivity deals taking power from doctors?
Modern Healthcare

Exclusivity deals for hepatitis C drugs by pharmacy benefit managers and a major health plan have raised concerns that the decision of which drug is best for a patient is being taken away from clinicians.Last week Anthem became the first payer to announce an exclusivity deal for a hepatitis C drug. As part of the pact, beneficiaries must try Gilead Sciences’ Harvoni before trying any other treatment for hepatitis C genotype 1, which accounts for up to 75% of all U.S. cases.